Amgen creates catalog of qualified tools and reagents to advance basic discoveries in biology

Amgen (NASDAQ: AMGN) today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology, as well as deepen relationships with academic institutions. This catalog and its associated materials are called the Amgen Biology-Enabling Resource (AmBER).

AmBER is comprised of more than 1,000 elements and includes small molecules, peptides, antibodies and recombinant proteins, engineered cell lines, and genetically-engineered mice. These are tools created to support discovery activities throughout Amgen's history and have been extensively validated in most cases.

"We see AmBER as an important contribution in our effort to connect with the academic community and to help advance scientific discovery," said Alexander Kamb, Ph.D., senior vice president of Discovery Research at Amgen. "AmBER will allow Amgen to further expand relationships around innovative biology and medicine and enhance research literature quality by providing qualified materials."

Amgen scientists and staff assembled these materials and have organized pertinent information into a searchable catalog. This catalog is available to designated institutions. Amgen will provide the materials on request as a donation to the cause of basic science—with no claim to ownership of intellectual property to discoveries that may ensue. As specific materials are depleted, Amgen anticipates others will be added so that AmBER continues as an evolving resource for academics.

SOURCE Amgen

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients